Zuclopenthixol dihydrochloride may leads to lower leaving the study early (any reason) compared with chlorpromazine (low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with chlorprothixene (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with haloperidol (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with perphenazine (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason, short and medium term) compared with risperidone (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with sulpiride (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with thiothixene (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride changes leaving the study early (any reason) compared with zuclopenthixol depot (very low certainty).
It is very uncertain whether zuclopenthixol dihydrochloride (Cis Z isomer) changes leaving the study early: Any reason compared with zuclopenthixol (Cis Z/Trans E isomer) (very low certainty).
It is very uncertain whether CLOZAPINE + AMISULPIRIDE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Genc 2007) (very low certainty).
It is very uncertain whether CLOZAPINE + RISPERIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + ZIPRASIDONE (Kuwilsky 2010) (very low certainty).
It is very uncertain whether CLOZAPINE + ZIPRASIDONE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + QUETIAPINE (Wen 2015) (very low certainty).
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
Corticosteroids probably leads to lower early clinical failure ‐ adults compared with control (moderate certainty).
Corticosteroids leads to lower early clinical failure ‐ adults ‐ severe CAP compared with control (high certainty).
Corticosteroids leads to lower early clinical failure ‐ adults ‐ non‐severe CAP compared with control (high certainty).